News
Silence Therapeutics is snatching back two siRNA drug | Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt Pharmaceuticals.
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback